Educators are innovators.
Use this page to describe your company's mission and goals. Nullam tempor dolor sed nulla auctor, nec placerat felis sodales. Etiam et turpis mattis, efficitur mi ut, ultrices diam. Donec consectetur, odio eget porta varius, orci mauris viverra ante, eget egestas turpis sapien vel orci. Donec eu ornare augue, ut efficitur velit. Vestibulum et magna mattis, sollicitudin ligula ac, facilisis dui. Ut blandit lectus neque.
Sit amet fringilla nisi mollis eget. Sed a eros nec leo euismod eleifend sit amet ut nisl blandit. Sed a eros nec leo euismod eleifend sit amet ut nisl. Nullam tempor dolor sed nulla auctor, nec placerat felis sodales. Etiam et turpis mattis, efficitur mi ut, ultrices diam. Donec consectetur, odio eget porta varius, orci mauris viverra ante, eget egestas turpis sapien vel orci mauris viverra.
ABOUT FairWoundCare.org
FairWoundCare.org was founded by wound care providers, manufacturers, distributors, and consultants and is dedicated to ensuring that access to high-quality and effective wound care treatments remain available to all patients.
Here is where FairWoundCare.org stands on skin substitute use in wound care:
The current state of skin substitute use in wound care is not sustainable largely due to lack of proper pricing policy and abuse. The Centers for Medicare and Medicaid Services (CMS) is right to seek appropriate controls regarding skin substitute price and usage, but attempting to achieve this measure through product exclusion is the wrong approach and will have detrimental impacts.
The rationale for the covered/non-covered list segmentation is not in alignment with FDA’s regulation of tissue products. If CMS is not going to cover products which are permitted to be marketed by FDA, CMS should set out clear requirements for evidence such that products can be covered fairly.
The limit of 4 applications means that statistically almost half of the wounds treated with HCT/P will be considered “exceptional” cases. This limit will almost certainly result in poorer outcomes, including morbidity. In many cases, these poorer short-term wound outcomes will translate to higher overall costs of care due to amputation.
Manufacturers should invoke pricing policies that favor a long-term, sustainable policy which maximizes the number of wounds treated.
CMS and the MACs should abandon the current LCD and draft a more thoughtful and workable policy which will not limit the number of wounds treated or negatively impact outcomes.
You can help ensure that CMS and the MACs do not move forward with the current proposal. Act now and let your voice be heard!
—
Simone Lemoniere
Executive Director, Mentor